Although the database did not include enough head and neck cancer cell lines for separate cohort analysis, the pan-cancer cohort showed significantly increased sensitivity (p = 0.0198) to cisplatin for cell lines with NSD1 mutations (n = 18) compared to those with wild-type NSD1 (n = 798) (Fig. 6A). The gene discussed is NSD1; the disease is head and neck cancer.